Ocular Surface Disease

In an interactive panel at the Twin Cities Ocular Surface Disease Symposium, speakers and attendees shared insight and experience with different treatment options and procedural techniques for patients with ocular surface disease.

Treatment with stem cells may be among the considerations in patients with ocular surface disease who have not responded to traditional therapy, according to a speaker at the Twin Cities Ocular Surface Disease Symposium.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, discusses data from the SAHARA trial, which evaluated patients with dry eye disease and meibomian gland dysfunction.

Hands-on workshops and high-level education engaged attendees at this year’s Twin Cities Ocular Surface Disease Symposium, which offered a host of events related to research, diagnosis and management of ocular surface disease.

The Twin Cities Ocular Surface Disease Symposium, Oct. 21-22 in Minneapolis, will include 12 hours of COPE continuing education credit and feature hands-on workshops with key devices and the latest in ocular surface disease technology.

When I am performing tests to determine a patient’s glaucoma status — visual fields, retinal nerve fiber layer measurements on OCT, fundus photography, etc — I will also examine their ocular surface and do meibomian gland imaging.

Ophthalmologists must pay attention to the state of the ocular surface to try to avoid unhappy patients after cataract surgery, according to a presentation from Real World Ophthalmology.

The third annual Twin Cities Ocular Surface Disease Symposium will be hosted Oct. 21 and 22 in Minneapolis and will include 12 hours of CE credit for both optometrists and ophthalmologists.

The Twin Cities Ocular Surface Disease Symposium, to be held Oct. 21 and 22 in Minneapolis, will offer 12 hours of accredited continuing education for eye care professionals, the symposium’s founder, Ahmad Fahmy, OD, FAAO, told Healio.